Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica : A scoping review by the OMERACT irAE working group. / Ghosh, Nilasha; Couette, Nina; van Binsbergen, Wouter H. et al.
In: Seminars in arthritis and rheumatism, Vol. 58, 152110, 01.02.2023.Research output: Contribution to journal › Review article › Academic › peer-review
}
TY - JOUR
T1 - Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica
T2 - A scoping review by the OMERACT irAE working group
AU - Ghosh, Nilasha
AU - Couette, Nina
AU - van Binsbergen, Wouter H.
AU - Weinmann, Sophia C.
AU - Jivanelli, Bridget
AU - Shea, Beverley
AU - Bass, Anne R.
AU - Benesova, Karolina
AU - Bingham, Clifton O.
AU - Calabrese, Cassandra
AU - Cappelli, Laura C.
AU - Chan, Karmela Kim
AU - Choy, Ernest
AU - Daoussis, Dimitrios
AU - Goodman, Susan
AU - Hudson, Marie
AU - Jamal, Shahin
AU - Leipe, Jan
AU - Lopez-Olivo, Maria A.
AU - Suarez-Almazor, Maria
AU - van der Laken, Conny J.
AU - Meara, Alexa Simon
AU - Liew, David
AU - Kostine, Marie
N1 - Funding Information: We would like to submit this on behalf of the OMERACT irAE working group. We would also like to thank Marianne Visser, an OMERACT Patient Research Partner. In memoriam: Uwe Preckwinkel, an OMERACT Patient Research Partner. Uwe was a German scientist and a cancer patient who experienced a rheumatic immune-related adverse event. He was involved in the OMERACT working group on rheumatic immune-related adverse events since its inception. Publisher Copyright: © 2022
PY - 2023/2/1
Y1 - 2023/2/1
N2 - Introduction: Immune checkpoint inhibitors (ICI), increasingly used cancer therapeutics, can cause off-target inflammatory effects called immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis (ICI-induced IA) and polymyalgia rheumatica (ICI-induced PMR). There are no validated classification criteria or outcome measures for these conditions, and adaptation of treatment recommendations from corresponding rheumatic diseases may not be appropriate. We summarized clinical descriptors of ICI-induced IA and ICI-induced PMR and aggregated domains used for these conditions in order to inform the development of a core set of outcome domains. Methods: As the initial step of the core domain set generation process, we systemically searched Medline (Pubmed), EMBASE, Cochrane, and CINHL through March 2021 to identify all studies that provide both clinical descriptions and domains relevant to ICI-induced IA and ICI-induced PMR. Domains were mapped to core areas, such as pathophysiological manifestations, life impact, resource use, and longevity/survival, as suggested by the OMERACT 2.1 Filter. Results: We identified 69 publications, over a third of which utilized non-specific diagnoses of “arthritis,” “arthralgia,” and/or “PMR”. Other publications provided the number, the distribution and/or names of specific joints affected, while others labeled the irAE as the corresponding rheumatic disease, such as rheumatoid arthritis or spondyloarthritis. Most distinct domains mapped to the pathophysiology/manifestations core area (24 domains), such as signs/symptoms (13 domains), labs (6 domains), and imaging (5 domains), with harm domains of adverse effects from irAE treatment and fear of irAE treatment decreasing ICI efficacy. Forty-three publications also referenced irAE treatment and 35 subsequent response, as well as 32 tumor response. Conclusion: There is considerable heterogeneity in the domains used to clinically characterize ICI-induced IA and ICI-induced PMR. There were several domains mapped to the pathophysiologic manifestations core area, although several publications highlighted domains evenly distributed among the other core areas of life impact, longevity/survival and resource use.
AB - Introduction: Immune checkpoint inhibitors (ICI), increasingly used cancer therapeutics, can cause off-target inflammatory effects called immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis (ICI-induced IA) and polymyalgia rheumatica (ICI-induced PMR). There are no validated classification criteria or outcome measures for these conditions, and adaptation of treatment recommendations from corresponding rheumatic diseases may not be appropriate. We summarized clinical descriptors of ICI-induced IA and ICI-induced PMR and aggregated domains used for these conditions in order to inform the development of a core set of outcome domains. Methods: As the initial step of the core domain set generation process, we systemically searched Medline (Pubmed), EMBASE, Cochrane, and CINHL through March 2021 to identify all studies that provide both clinical descriptions and domains relevant to ICI-induced IA and ICI-induced PMR. Domains were mapped to core areas, such as pathophysiological manifestations, life impact, resource use, and longevity/survival, as suggested by the OMERACT 2.1 Filter. Results: We identified 69 publications, over a third of which utilized non-specific diagnoses of “arthritis,” “arthralgia,” and/or “PMR”. Other publications provided the number, the distribution and/or names of specific joints affected, while others labeled the irAE as the corresponding rheumatic disease, such as rheumatoid arthritis or spondyloarthritis. Most distinct domains mapped to the pathophysiology/manifestations core area (24 domains), such as signs/symptoms (13 domains), labs (6 domains), and imaging (5 domains), with harm domains of adverse effects from irAE treatment and fear of irAE treatment decreasing ICI efficacy. Forty-three publications also referenced irAE treatment and 35 subsequent response, as well as 32 tumor response. Conclusion: There is considerable heterogeneity in the domains used to clinically characterize ICI-induced IA and ICI-induced PMR. There were several domains mapped to the pathophysiologic manifestations core area, although several publications highlighted domains evenly distributed among the other core areas of life impact, longevity/survival and resource use.
KW - ICI-induced inflammatory arthritis
KW - ICI-induced polymyalgia rheumatica
KW - Immune checkpoint inhibitor
KW - Outcome measures
UR - http://www.scopus.com/inward/record.url?scp=85141527194&partnerID=8YFLogxK
U2 - 10.1016/j.semarthrit.2022.152110
DO - 10.1016/j.semarthrit.2022.152110
M3 - Review article
C2 - 36372016
VL - 58
JO - Seminars in arthritis and rheumatism
JF - Seminars in arthritis and rheumatism
SN - 0049-0172
M1 - 152110
ER -
ID: 27114498